CorticorpNews
Back to Finance
Expand

Updated

Eli Lilly beat third-quarter estimates on October 29, 2026, and raised its sales outlook as demand for Zepbound and Mounjaro stayed strong. The company reported that sales of its obesity drug Zepbound and diabetes treatment Mounjaro surged again in the quarter. Further figures were not included in the available headline coverage.

Sources:CNBC Top News

1 outlet · 1 article · first seen Oct 29, 7:10 AM ET

What this touches in markets

Stored closes for the instruments tied to this story's tags and places, with their dates.

  • XLV closed at 179.72, up 0.30%, on 2026-10-28. Listed for: Health Care sector ETF.

Every source article